These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 28916483)
21. Bevacizumab revisited: its use in different mouse models of ocular pathologies. Hollanders K; Van Bergen T; Van de Velde S; Sijnave D; Vandewalle E; Moons L; Stalmans I Curr Eye Res; 2015 May; 40(6):611-21. PubMed ID: 25117905 [TBL] [Abstract][Full Text] [Related]
22. DS-7080a, a Selective Anti-ROBO4 Antibody, Shows Anti-Angiogenic Efficacy with Distinctly Different Profiles from Anti-VEGF Agents. Isumi Y; Hayashi S; Inoue T; Yoshigae Y; Sato T; Hasegawa J; Agatsuma T Transl Vis Sci Technol; 2020 Aug; 9(9):7. PubMed ID: 32879763 [TBL] [Abstract][Full Text] [Related]
23. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Algvere PV; Steén B; Seregard S; Kvanta A Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062 [TBL] [Abstract][Full Text] [Related]
24. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N; Damico L; Shams N; Lowman H; Kim R Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284 [TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Abrams P Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187 [TBL] [Abstract][Full Text] [Related]
26. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075 [TBL] [Abstract][Full Text] [Related]
28. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Ren X; Li J; Xu X; Wang C; Cheng Y Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788 [TBL] [Abstract][Full Text] [Related]
29. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization. Toledano S; Lu H; Palacio A; Ziv K; Kessler O; Schaal S; Neufeld G; Barak Y PLoS One; 2016; 11(12):e0168122. PubMed ID: 28036336 [TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A Acta Ophthalmol; 2008 Nov; 86 Thesis 4():42-9. PubMed ID: 19032681 [TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]